Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract

Area of Science:

• Oncology
• Gastroenterology
• Molecular Biology

Background:

• Gastrointestinal (GI) toxicity is a major dose-limiting side effect of cancer chemotherapy.
• Understanding the precise molecular mechanisms and regional gene expression changes in the GI tract following chemotherapy is crucial but incompletely understood.

Purpose of the Study:

• To investigate gene expression profiles in different regions of the GI tract after irinotecan treatment.
• To correlate these gene expression changes with markers of cell death and tissue damage.
• To identify time- and site-specific molecular responses to chemotherapy-induced GI insult.

Main Methods:

• Microarray analysis of gene expression in various GI tract regions following irinotecan administration.
• Assessment of cell death markers and tissue damage severity.
• Real-time PCR validation of mitogen-activated protein kinase (MAPK) signaling pathway gene expression.

Main Results:

• Early upregulation (within 6 hours) of genes involved in apoptosis, MAPK signaling, and inflammation.
• Later upregulation (up to 72 hours) of genes related to cell proliferation, wound healing, and angiogenesis.
• Significant increase in cell death at 6 and 24 hours; the stomach exhibited the least tissue damage.
• Jejunum and colon showed increased MAPK pathway gene expression at 72 hours, while the stomach remained unchanged.

Conclusions:

• GI tissue damage severity is influenced by the timing and location of specific gene responses to chemotherapy.
• Targeting key gene responses at appropriate time points could be a strategy to prevent chemotherapy-induced GI toxicity.
• Understanding regional GI tract responses to irinotecan provides insights into managing treatment-related side effects.